Pfizer Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $7.77B | $8.03B | $2.12B | $31.37B | $21.98B | $9.16B | $16.03B | $11.15B |
| Depreciation & Amortization | $6.59B | $7.01B | $6.29B | $5.06B | $5.19B | $4.68B | $5.76B | $6.38B |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | $5.30B | $4.70B | $3.60B | $3.70B | $3.40B | $4.50B | — |
| Stock-Based Compensation | $799.0M | $877.0M | $525.0M | $872.0M | $1.18B | $755.0M | $687.0M | $923.0M |
| Net Cash from Operating Activities | $11.70B | $12.74B | $8.70B | $29.27B | $32.58B | $14.40B | $12.59B | $15.83B |
| Investing Activities | ||||||||
| Capital Expenditures | $2.63B | $2.91B | $3.91B | $3.24B | $2.71B | $2.23B | $2.05B | $1.98B |
| Business Acquisitions | $6.93B | $0 | $43.43B | $23.00B | $0 | $0 | $10.86B | $0 |
| Net Cash from Investing Activities | $-1.35B | $2.65B | $-32.28B | $-15.78B | $-22.55B | $-4.27B | $-3.95B | $4.53B |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $0 | $0 | $2.00B | $0 | $0 | $8.87B | $12.20B |
| Net Cash from Financing Activities | $-10.30B | $-17.14B | $26.07B | $-14.83B | $-9.82B | $-9.65B | $-8.49B | $-20.44B |
| Net Change in Cash | $91.0M | $-1.81B | $2.45B | $-1.52B | $159.0M | $475.0M | $125.0M | $-205.0M |
| Free Cash Flow | $9.08B | $9.84B | $4.79B | $26.03B | $29.87B | $12.18B | $10.54B | $13.84B |